Trademark: 88037659
Word
IO2 INTERVENTIONAL & IMMUNO-ONCOLOGY
Status Date
Friday, January 12, 2024
Filing Date
Friday, July 13, 2018
5 Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical purposes; transarterial chemoembolization pharmaceutical preparations, vaccines and sera; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes; radiopharmaceuticals; therapeutic agents for delivery of radioactive material to target sites within the body; radioactive substances for medical purposes, namely, microscopic radioactive beads for treatment of cancerous tumours, microscopic glass beads incorporating radioactive material for treatment of cancerous tumours, and radioactive glass beads; pharmaceutical preparations for use in chemotherapy
10 Surgical apparatus and instruments; medical apparatus and instruments for use in the diagnosis and treatment of cancer; Surgical and medical apparatus and instruments, namely, drug delivery systems; apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolisation; drug delivery embolisation systems; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; implantable radiation therapy devices, namely, microscopic glass beads incorporating radioactive material or containing radioactive material and administered surgically for treatment of cancerous tumours, and radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; needles for medical use, namely, cannula needles; medical devices for performing cryotherapy, namely, cryosurgical probes and cryoablation needles used for the minimally invasive cryoablation of cancerous tissues; medical apparatus consisting of treatment probes and high pressure valves used for heat or freeze treatment; surgical, medical and medical diagnostic devices, apparatus and instruments for use in cryoablation, and the treatment of prostate cancer, kidney or renal tumours, and benign prostatic hyperplasia (BPH); medical devices used to deliver heat to target sites using electrical current through needles; medical devices to deliver cryogen gas for freezing and either cryogen gas or electrical current for heating; medical devices for ablating human and animal tissue using microwave energy; medical devices for treating cancerous and benign tissue using microwave energy; replacement and structural parts for all of the aforesaid goods
The mark consists of the words "INTERVENTIONAL &" above the word "IMMUNO-ONCOLOGY" to the right of a stylized depiction of "IO" with the number "2" in superscript to the right of "IO" in a box.
IO TWO INTERVENTIONAL AND IMMUNO-ONCOLOGY
Color is not claimed as a feature of the mark.
"INTERVENTIONAL & IMMUNO-ONCOLOGY"
Jan 12, 2024
Report Completed Suspension Check Case Still Suspended
Jul 15, 2023
Report Completed Suspension Check Case Still Suspended
Jul 14, 2023
Report Completed Suspension Check Case Still Suspended
Mar 16, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Mar 16, 2023
Teas Change Of Correspondence Received
Mar 16, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Mar 16, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Mar 16, 2023
Teas Change Of Owner Address Received
Jan 3, 2023
Report Completed Suspension Check Case Still Suspended
Jun 9, 2022
Report Completed Suspension Check Case Still Suspended
Dec 9, 2021
Report Completed Suspension Check Case Still Suspended
Jun 9, 2021
Report Completed Suspension Check Case Still Suspended
Dec 9, 2020
Report Completed Suspension Check Case Still Suspended
Aug 30, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 30, 2020
Teas Change Of Correspondence Received
Aug 30, 2020
Teas Withdrawal Of Attorney Received-Firm Retains
Aug 30, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 30, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 30, 2020
Teas Change Of Owner Address Received
Jun 9, 2020
Report Completed Suspension Check Case Still Suspended
Dec 5, 2019
Notification Of Letter Of Suspension E-Mailed
Dec 5, 2019
Letter Of Suspension E-Mailed
Dec 5, 2019
Suspension Letter Written
Dec 4, 2019
Teas/Email Correspondence Entered
Dec 3, 2019
Correspondence Received In Law Office
Dec 3, 2019
Teas Response To Office Action Received
Jul 2, 2019
Notification Of Non-Final Action E-Mailed
Jul 2, 2019
Non-Final Action E-Mailed
Jul 2, 2019
Non-Final Action Written
May 21, 2019
Teas/Email Correspondence Entered
May 21, 2019
Correspondence Received In Law Office
May 19, 2019
Assigned To Lie
May 10, 2019
Teas Response To Office Action Received
Nov 20, 2018
Notification Of Non-Final Action E-Mailed
Nov 20, 2018
Non-Final Action E-Mailed
Nov 20, 2018
Non-Final Action Written
Oct 31, 2018
Assigned To Examiner
Jul 19, 2018
Teas Amendment Entered Before Attorney Assigned
Jul 19, 2018
Teas Voluntary Amendment Received
Jul 19, 2018
Notice Of Design Search Code E-Mailed
Jul 18, 2018
New Application Office Supplied Data Entered
Jul 17, 2018
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
